Efficacy and safety of D,L-3-hydroxybutyrate (D,L-3-HB) treatment in multiple acyl-CoA dehydrogenase deficiency. by van Rijt, Willemijn J et al.
Efficacy and safety of D,L-3-hydroxybutyrate (D,L-3-HB)
treatment in multiple acyl-CoA dehydrogenase deficiency
Willemijn J. van Rijt, MD1, Emmalie A. Jager, BSc1, Derk P. Allersma, PhD2,
A. Çiğdem Aktuğlu Zeybek, MD3, Kaustuv Bhattacharya, MD, PhD4,
François-Guillaume Debray, MD, PhD5, Carolyn J. Ellaway, MBBS, PhD4, Matthias Gautschi, MD, PhD6,
Michael T. Geraghty, MD PhD7, David Gil-Ortega, MD, PhD8, Austin A. Larson, MD9,
Francesca Moore, BSc10, Eva Morava, MD, PhD11,12, Andrew A. Morris, MD, PhD13,14,
Kimihiko Oishi, MD15, Manuel Schiff, MD, PhD16, Sabine Scholl-Bürgi, MD, PhD17,
Michel C. Tchan, MD, PhD18, Jerry Vockley, MD, PhD19, Peter Witters, MD, PhD12,
Saskia B. Wortmann, MD, PhD20,21,22, Francjan van Spronsen, MD, PhD1,
Johan L. K. Van Hove, MD, PhD9 and Terry G. J. Derks, MD, PhD 1
Purpose:Multiple acyl-CoA dehydrogenase deficiency (MADD) is
a life-threatening, ultrarare inborn error of metabolism. Case
reports described successful D,L-3-hydroxybutyrate (D,L-3-HB)
treatment in severely affected MADD patients, but systematic data
on efficacy and safety is lacking.
Methods: A systematic literature review and an international,
retrospective cohort study on clinical presentation, D,L-3-HB
treatment method, and outcome in MADD(-like) patients.
Results: Our study summarizes 23 MADD(-like) patients, includ-
ing 14 new cases. Median age at clinical onset was two months
(interquartile range [IQR]: 8 months). Median age at starting D,L-3-
HB was seven months (IQR: 4.5 years). D,L-3-HB doses ranged
between 100 and 2600mg/kg/day. Clinical improvement was
reported in 16 patients (70%) for cardiomyopathy, leukodystrophy,
liver symptoms, muscle symptoms, and/or respiratory failure. D,L-
3-HB appeared not effective for neuropathy. Survival appeared
longer upon D,L-3-HB compared with historical controls. Median
time until first clinical improvement was one month, and ranged up
to six months. Reported side effects included abdominal pain,
constipation, dehydration, diarrhea, and vomiting/nausea. Median
D,L-3-HB treatment duration was two years (IQR: 6 years). D,L-3-
HB treatment was discontinued in 12 patients (52%).
Conclusion: The strength of the current study is the international
pooling of data demonstrating that D,L-3-HB treatment can be
effective and safe in MADD(-like) patients.
Genetics in Medicine (2020) https://doi.org/10.1038/s41436-019-
0739-z
Keywords: D,L-3-hydroxybutyrate treatment; fatty acid oxida-
tion; inborn error of metabolism; ketone bodies; multiple acyl-CoA
dehydrogenase deficiency
INTRODUCTION
Multiple acyl-CoA dehydrogenase deficiency (MADD; also
known as glutaric aciduria type II, OMIM 231680) is an
ultrarare (i.e., <1:50,000) inborn error of metabolism (IEM).
MADD can be primary, caused by a genetic defect in the
electron transfer flavoproteins (ETF) or in ETF dehydrogen-
ase (ETFDH), or secondary, resulting from genetic defects of
riboflavin transport (RFVT) or flavin adenine dinucleotide
(FAD) synthesis (i.e., MADD-like disease). The impairment
of mitochondrial fatty acid oxidation (FAO) and amino acid
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metabolism causes energy deficiency and the accumulation of
toxic metabolites, such as medium-chain and long-chain
length plasma acylcarnitines, urinary organic acids (e.g.,
isovaleric-, isobutyric-, 2-methylbutyric-, glutaric-, ethylma-
lonic-, 3-hydroxyisovaleric-, 2-hydroxyglutaric-, 5-hydroxy-
hexanoic-, and several dicarboxylic acids) and urinary
acylglycines (e.g., isovalerylglycine, isobutyrylglycine, and 2-
methylbutyrylglycine).1
Historically, MADD patients are classified into three
categories: patients with a severe, neonatal onset with or
without congenital anomalies (type I or II, respectively), and
patients with a relatively mild, later onset (type III).1 Type I
and II patients often demonstrate life-threatening symptoms
including metabolic derangements, cardiomyopathy, leuko-
dystrophy, and severe hypotonia. The clinical course in type
III patients can vary from recurrent hypoglycemia to lipid
storage myopathy and exercise intolerance.1 Treatment
options include dietary fat and protein restriction, fasting
avoidance, and supplementation with carnitine, glycine, and/
or riboflavin, when riboflavin responsive. Despite early
diagnosis and treatment, morbidity and mortality remain
high in neonatal onset patients.1
Upon prolonged fasting, hepatic mitochondrial FAO fuels
synthesis of ketone bodies (KB) acetoacetate and 3-hydro-
xybutyrate, as important alternative energy sources for the
brain, skeletal muscle, and heart.2–4 Patients with mitochon-
drial FAO disorders, such as MADD, demonstrate multiorgan
dysfunction especially during catabolism.2 Administration of
exogenous KB might bypass the disturbed ketogenesis. Several
case reports described successful treatment of severely affected
MADD patients with racemic D,L-3-hydroxybutyrate (D,L-3-
HB).5–9 The lack of systematic data on efficacy and safety of D,
L-3-HB hampers the treatment of seriously ill patients and
prevents D,L-3-HB reimbursement. Therefore, we performed a
twofold study including a systematic literature review and an
international, retrospective cohort study to describe the clinical
presentations of MADD(-like) patients treated with D,L-3-HB,
the details of D,L-3-HB treatment methods, and outcomes.
MATERIALS AND METHODS
The Medical Ethical Committee of the University Medical
Center Groningen confirmed that the Medical Research
Involving Human Subjects Act does not apply and that
official approval of this study by the Medical Ethical
Committee was not required (METc code 2016/470). The
study protocol was performed in compliance with the
Declaration of Helsinki and approved for waiver of consent
by all participating institutes or performed conforming to the
laws and regulations of the respective countries and institutes.
Systematic literature review
To identify all reported IEM patients treated with D,L-3-HB
and their health-care providers, a comprehensive search
strategy for relevant publications before 21 December 2016
was performed in PubMed and EMBASE public databases.
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines were followed as accurately as
possible. The detailed search strategy, a protocol of the
screening process and data extraction, a flowchart, and the
PRISMA-P 2015 checklist are presented in Supplementary
Data 1. Articles were included based on the presence of
detailed patient data concerning D,L-3-HB- or KB treatment,
as well as a confirmed diagnosis by biochemical (acylcarnitine
or urinary organic acid profile), DNA, or enzymatic analysis.
Exclusion criteria were (1) no detailed patient data described,
(2) lack of accessibility of the abstracts or articles, and (3) no
availability in English or Dutch language.
Retrospective cohort study
In February 2017 health-care providers with experience in D,
L-3-HB treatment of MADD(-like) patients were invited to
collaborate in this study by contacting (1) the first and/or
corresponding authors of previous publications, identified in
our systematic literature study; (2) clinicians who have
previously contacted the authors (J.L.K.V.H. or T.G.J.D.) on
this topic; (3) several professional organizations and net-
works, including a list server for the metabolic community
(Metab-l), Society for the Study of Inborn Errors of
Metabolism (SSIEM), Society for Inherited Metabolic Dis-
orders (SIMD), and the European Reference Network for
Hereditary Metabolic Diseases (MetabERN).
D,L-3-HB treatment has been reported in at least two
MADD-like patients who were later found to have RFVT
defects.10,11 Patients with genetic defects of RFVT (i.e.,
SLC52A1, SLC52A2, SLC52A3 [alias C20orf54]) and FAD
metabolism (i.e., SLC25A32, FLAD1) were, therefore, included
in this study in addition to those with ETF or ETF
dehydrogenase defects. MADD(-like) patients were eligible
for enrollment in case of a diagnosis confirmed by
biochemical, DNA, or enzymatic analysis, performed con-
forming to local protocols. Outcome parameters included data
on clinical presentation, laboratory and molecular parameters,
D,L-3-HB treatment method, and (long-term) outcome. Data
was collected via an anonymous questionnaire in Microsoft
Word to be completed by health-care providers involved.
Data inclusion was concluded in December 2018, after which
data from all completed questionnaires were summarized.
The STROBE checklist for reporting observational studies is
presented in Supplementary Data 2.
Statistical analysis
Data analysis was performed using Microsoft Excel and
GraphPad Prism, version 5.0 (GraphPad Software, La Jolla,
CA). Descriptive statistics were used to summarize the data.
Categorical and continuous variables are presented as
numbers (percentages) or median (interquartile range
[IQR]), respectively. Kaplan–Meier plots were used to
estimate the survival and visualize the data on time until first
reported clinical improvement and D,L-3-HB treatment
duration. The survival of MADD(-like) patients treated with
D,L-3-HB was compared with survival data from historical
controls who were not reported to have been treated with D,
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L-3-HB, as collected in a previous meta-analysis.12
Mann–Whitney U test was used to analyze the significance
of differences between groups. If data were missing, the
analysis was performed on data from the remaining patients.
A p value of <0.05 was considered statistically significant.
RESULTS
Systematic literature review
Supplementary Table 1 summarizes data from 14 references
on D,L-3-HB treatment in 16 patients with MADD(-like)
disease.2,5–8,10,11,13–19 Additionally, D,L-3-HB treatment was
reported in 18 patients with other IEMs in which ketogenesis
is disturbed, demonstrating potential indications of the
compound. These IEMs included carnitine–acylcarnitine
translocase deficiency (n= 1),17,18 glycogen storage disease
type III (n= 3),20,21 3-hydroxy-3-methylglutaryl-coenzyme A
lyase deficiency (n= 4),17,18,22,23 mitochondrial complex IV
deficiency (n= 2),20 persistent hyperinsulinemic hypoglyce-
mia of infancy (n= 6),24,25 propionic acidemia (n= 1),20 and
very long-chain acyl-CoA dehydrogenase deficiency (n= 1).20
Retrospective cohort study
Patient characteristics
In total, 23 MADD(-like) patients treated with D,L-3-HB
treatment were identified, including 14 novel cases. The
individual patient characteristics are presented in Table 1.
Median age at clinical ascertainment was two months (IQR:
8 months). Nine patients (39%) had a neonatal disease onset
and all presented clinically during the first week of life.
Structural congenital anomalies were not reported. Hence,
they were classified as type II patients. The 14 remaining
patients (61%) could be categorized as type III patients,
including two with a clinical onset during adulthood.
Abnormal population newborn screening results were
observed in 14 patients (61%) of whom eight (57%) developed
clinical symptoms and signs during the first week of life.
Diagnosis was molecularly confirmed in 20 cases (87%)
(pathogenic variants in ETFA [n= 4], ETFDH [n= 6];
compound heterozygosity in ETFA [n= 2], ETFDH [n= 6],
SLC52A3 [n= 2]). In one patient in whom DNA analysis was
inconclusive, the results of an enzyme assay were indicative of
MADD. All reported acylcarnitine profiles (n= 18) and
urinary organic acid profiles (n= 22) at diagnosis demon-
strated at least mild abnormalities consistent with MADD.
D,L-3-hydroxybutyrate treatment method
In our cohort of patients, D,L-3-HB was prescribed as a food
supplement (KetoForce) in one patient, and as hospital
pharmacy constituted formulation or prepared by a caregiver
in others, after being obtained from various suppliers
including Huddersfield Pharmacy Specials, Inresa, M2i,
Sigma-Aldrich, and Special Products Ltd (Veriton Pharma).
The most reported formulation involved a racemic sodium
salt. Currently, in The Netherlands, the D,L-3-HB is
magistrally prepared as a 593.3 mg/mL (4.7 M) solution in
distilled water. The D,L-3-HB is acquired by Sigma-Aldrich
and this treatment costs €0.0040/mg (price for the active
ingredient only and a simple product formulation) averaging
approximately €3.60/kg/day at an assumed starting dose of
900 mg/kg/day.
The median age at start of D,L-3-HB treatment was seven
months (IQR: 4.5 years). Prescribed doses ranged between 100
and 2600mg/kg/day, divided in one to six daily doses. Five
patients (22%) received D,L-3-HB continuously during the night
and one patient (4%) continuously for 24 hours per day. The D,
L-3-HB was administered orally or via nasogastric/gastrostomy
tube, usually combined with nutrition or before/after the meal.
D,L-3-hydroxybutyrate treatment outcome
Patient and treatment characteristics according to outcome are
summarized in Table 2. Individual D,L-3-HB treatment
characteristics and outcome are presented in Supplementary
Table 2. In total, clinical improvement upon D,L-3-HB was
reported in 16 patients (70%) for cardiomyopathy, leukodystro-
phy, liver symptoms (i.e., hyperammonemia, hypoglycemia, liver
dysfunction or failure, and metabolic acidosis), muscle symp-
toms (i.e., exercise intolerance, hypotonia, myopathy, and
rhabdomyolysis), and/or respiratory failure. D,L-3-HB treatment
was effective in 6/9 type II patients (67%). The efficacy was
questionable in two type II patients (22%) in whom D,L-3-HB
was used as a preventive measure, which complicated the
interpretation of treatment outcomes. Clinical improvement was
also reported in 10/14 type III patients (71%), including a patient
with RFVT3 deficiency. The efficacy was questionable in one
type III patient (7%) because the duration of treatment was only
three months at the time of data analysis. Additional follow-up
demonstrated that the patient remained clinically stable without
further deterioration of the leukodystrophy. D,L-3-HB was
ineffective in 1 type II (11%) and 3 type III patients (21%), of
whom one patient was diagnosed with RFVT3 deficiency. The
treatment indications in those patients included muscle and liver
symptoms, respiratory failure, and neuropathy with the
maximum prescribed doses ranging between 750 and 1800
mg/kg/day. Figure 1a presents the summarized organ-based D,
L-3-HB treatment indications and efficacy. Symptom-specific
indications and efficacy are demonstrated in Supplementary
Fig. 1. Compared with data from historical controls (i.e., 26 type
II patients), the survival appeared longer in type II MADD(-like)
patients treated with D,L-3-HB, as shown in Fig. 1b. The median
interval from start of D,L-3-HB to first reported clinical
improvement was one month (IQR: 3 months) and ranged up
to six months, as demonstrated in Fig. 1c. Three of four patients
(75%) in the group of nonresponders and 1/3 patients (33%) in
the group with questionable efficacy had a treatment duration of
more than six months.
The following side effects of D,L-3-HB were reported in 8
patients (35%): abdominal pain, constipation, dehydration,
diarrhea, and vomiting or nausea. Detailed data on D,L-3-HB
safety are presented in Fig. 2. D,L-3-HB treatment related
(treatment duration >1 day) side effects appeared to be dose
dependent with a median maximum dose of 600 mg/kg/day
(IQR: 410 mg/kg/day) in patients without side effects
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compared with 950 mg/kg/day (IQR: 555 mg/kg/day) in
patients with side effects (p= 0.0544). In four patients
(17%), the D,L-3-HB dose was titrated based upon biochem-
ical parameters, including (peak) concentrations of D-3-HB in
plasma, blood, and urine, and ammonia concentrations.
The median duration of D,L-3-HB treatment in the whole
cohort was two years (IQR: 6 years) and is demonstrated in
Fig. 3, categorized according to D,L-3-HB treatment efficacy.
Treatment was discontinued in 12 patients (52%) due to
(combinations of) clinical improvement after which further
D,L-3-HB treatment was deemed unnecessary (n= 2), lack of
clinical improvement (n= 2), death irrespective of the cause
(n= 5), side effects (n= 1), noncompliance (n= 1), and costs
(n= 2). The median age at D,L-3-HB discontinuation was
three years (IQR: 13.5 years). The median treatment duration
before D,L-3-HB discontinuation was 10 months (IQR: 1.5
years), while in the patients who continued D,L-3-HB
treatment, the median treatment duration was 6.5 years
(IQR: 7 years). In patients who died during the course of D,L-
3-HB treatment, the median D,L-3-HB treatment duration
was 8 months (IQR: 4 months).
DISCUSSION
D,L-3-HB treatment is unlicensed but has been reported in at
least eight IEMs in which exogenous KB treatment may be
indicated. In 70% of the presented cohort of 23 MADD(-like)
patients, we observed clinical improvement of cardiomyo-
pathy, leukodystrophy, liver symptoms, muscle symptoms,
and respiratory failure upon start of D,L-3-HB treatment. D,
L-3-HB treatment appeared to be ineffective for neuropathy.
Side effects occurred in 35% of the patients but were never a
reason to discontinue supplementation in patients who
experienced clinical improvement.
To date, there are no clinical or laboratory parameters
predicting clinical efficacy of D,L-3-HB treatment, such as
phenotype, genotype, or age at start of D,L-3-HB treatment.
In our study, symptom improvement is observed up to six
months after commencing D,L-3-HB. It was not possible to
relate the (timespan of) D,L-3-HB treatment efficacy to age at
clinical onset, D,L-3-HB dosing, or to a specific organ because
in a number of patients there were several concurrent
treatment indications. The authors emphasize the importance
of a relatively long evaluation period for assessment of
efficacy, because clinical improvement occurs in weeks or
months rather than days after starting D,L-3-HB treatment.
Furthermore, studies are warranted to identify MADD (bio)
markers that correlate with clinical severity and can be used as
outcome parameters during prospective trials.12
Biochemical monitoring of D,L-3-HB treatment was
performed in only four patients (17%), all of whom
experienced clinical improvement. D,L-3-HB dose titration
toward at least detectable concentrations in blood, plasma, or
urine can indicate that a sufficient amount of exogenous KB is
supplied. Stable isotope infusion studies demonstrated an
increased endogenous KB production in fasting healthy
newborns compared with healthy adults.26,27 Thus, when
endogenous KB production rates are insufficient, it may be
hypothesized that exogenous requirements are higher in
infants. Prospective in vitro and (stable isotope) in vivo
metabolic flux studies may help guide the (individualized)
dose response curves and relations to symptoms and signs.
Table 2 Summarized patient and D,L-3-hydroxybutyrate
treatment characteristics according to outcome.
Clinical improvement upon D,L-3-HB
treatment
Yes
(n= 16; 70%)
Questionable
(n= 3; 13%)
No
(n= 4; 17%)
Gender M:F= 9:7 M:F= 1:2 M:F= 0:4
Alive 12 (75%) 2 (67%) 3 (75%)
Current age 13 years
(6.5 years)
3 years
(1.5 years)
13.5 years
(10.5 years)
Age at death 1.5 years
(8 years)
8 months 10 days
Age at onset 3months
(8 months)
3 days
(5 months)
3 months
(5 years)
Congenital anomalies - - -
Positive NBS results 8 (50%) 3 (100%) 2 (50%)
Genetic analysis 14 (88%) 3 (100%) 4 (100%)
ETFA 5a - 1
ETFB - - -
ETFDH 8 3 2b
SLC52A3 1 - 1
Enzyme assay 6 (38%) 1 (33%) 2 (50%)
ETF deficiency 1 - -
ETF-QO deficiency 4c 1 1
D,L-3-HB treatment
Age at start 1.5 years
(6 years)
6 months
(2 years)
5 months
(6.5 years)
Minimum D,L-3-HB
dose (mg/kg/day)
330 (215) 200 (105) 490 (215)
Maximum D,L-3-HB
dose (mg/kg/day)
650 (400) 395 (925) 905 (330)
Maximum number of
doses/day
4 (0.3)d 4 (1.5) 4 (0.5)e
D,L-3-HB
discontinuation
7 (44%) 2 (33%) 3 (75%)
Age at
discontinuation
6 years
(17 years)
1 year (5
months)
3.5 years
(13 years)
D,L-3-HB treatment
duration
3 years
(7.5 years)
6 months (5
months)
2 years
(3.5 years)
Values are presented as number of patients or median (interquartile range [IQR]).
NBS newborn screening.
aIn one patient, DNA analysis also demonstrated compound heterozygous variants
in ETFB (c.217–4G>T and c.438+20C>T), which were classified as variant of
uncertain significance and likely benign, respectively.
bIn one patient only one pathogenic variant identified.
cIn one patient only performed in sister.
dContinuous nocturnal administration (n= 4).
eContinuous nocturnal administration (n = 1) and continuous 24-hour administra-
tion (n = 1).
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In this study, the risk of side effects due to D,L-3-HB
appeared to increase with dose. However, frequently reported
side effects such as abdominal pain, constipation, dehydra-
tion, diarrhea, and vomiting or nausea are difficult to
discriminate from the natural course of the underlying
disorder and from intercurrent illness. In addition, it is
important to realize that the salt-free dose between different
compounds can differ. It is unclear whether the adverse effects
would be caused by the high amount of D,L-3-HB or by the
associated cation load. A relatively low dose of 600 mg/kg/day
of sodium-D,L-3-HB provides 4.8 mmol/kg/day of sodium,
and a high dose of 2600 mg/kg/day provides 20.6 mmol/kg/
day of sodium, compared with the normal sodium intake of 1
and 3–4 mmol/kg/day for adults and infants and young
children, respectively. Nevertheless, it should be emphasized
that in our study the benefits of D,L-3-HB appeared to
outweigh the side effects. Recently, D,L-3-HB treatment in the
form of a sodium or calcium salt was described in an MADD
patient. Severe alkalosis and hypernatremia were reported
after D,L-3-HB doses above 1400 mg/kg/day.9 Hypothetically,
the alkalosis might be caused by the high cation load or the
conjugate base excess of dissolved D,L-3-HB.9,28 The high
sodium load is also associated with increased calcium loss and
alkalization of urine, which can lead to nephrocalcinosis and
renal stones.9,28 Sufficient hydration is recommended for
these associated electrolyte challenges. Future studies are
warranted to investigate the influence of D,L-3-HB on fluid,
electrolyte, and acid–base homeostasis.
The mode of action of D,L-3-HB treatment is incompletely
understood and several mechanisms likely act simultaneously.
In mitochondrial FAO disorders, next to intracellular energy
deficiency and accumulation of toxic metabolites, shortage of
KB impairs cholesterol synthesis, which is required for
myelination.29 Endogenous 3-hydroxybutyrate also has sev-
eral direct and indirect signaling functions including gene
expression and activation of hydroxycarboxylic acid receptor
2, which is associated with reduced lipolysis as well as anti-
inflammatory and neuroprotective effects.30,31 Presumably,
this all targets the complex pathophysiology and clinical
manifestations in MADD patients, such as cardiomyopathy,
leukodystrophy, and myopathy. In MADD-like disorders, a
different working mechanism can be proposed. D,L-3-HB
treatment was also effective in one patient suffering from
RFVT3 deficiency in whom the treatment indication included
respiratory failure due to diaphragm paralysis and muscle
symptoms. It can be hypothesized that D,L-3-HB treatment
acts on the glutamate excitotoxicity and generation of reactive
oxygen species, which are potentially induced by riboflavin
deficiency and mitochondrial dysfunction.30,32–35 Addition-
ally, exogenous D,L-3-HB can provide a therapeutic option in
selected cases of other IEMs in which ketogenesis is impaired,
such as mitochondrial FAO disorders, defects of FAD
metabolism, glycogen storage disease, mitochondrial respira-
tory chain disorders, organic acidurias, or hyperinsulinism,
and as an additive for patients using a ketogenic diet.
3-Hydroxybutyrate is a chiral molecule with two enantio-
mers: D-3-hydroxybutyrate and L-3-hydroxybutyrate. Com-
pared with D-3-hydroxybutyrate, utilization of L-3-
hydroxybutyrate appears slower and through different
routes.28,36 Metabolism of D-3-hydroxybutyrate yields two
molecules of acetyl-CoA, which enter the Krebs cycle.31 After
mitochondrial import likely via monocarboxylate transporter
1,37 L-3-hydroxybutyrate is activated to L-3-hydroxybutyryl-
CoA by a specific coenzyme A ligase and becomes a substrate
for short-chain acyl-CoA dehydrogenase.38–41 Although
effects that depend on 3-hydroxybutyrate catabolism might
primarily be induced by D-3-hydroxybutyrate, L-3-
hydroxybutyrate may have its own specific utility. The
primary use of L-3-hydroxybutyrate seems to be in the
central nervous system, where the key enzymes are most
expressed.36 In rats, L-3-hydroxybutyrate seems to be the
preferred substrate for synthesis of fatty acids and sterols in
spinal cord, brain, and kidney, while D-3-hydroxybutyrate is
favored for oxidation.36,39 Future studies should evaluate if L-
3-hydroxybutyrate may have a specific therapeutic role
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Fig. 2 Safety of D,L-3-hydroxybutyrate treatment. The (serious) adverse
effects that occurred in a total of 13 multiple acyl-CoA dehydrogenase
deficiency (MADD)(-like) patients during the course of D,L-3-HB treatment.
Fig. 1 Efficacy of D,L-3-hydroxybutyrate treatment. a Proportion of multiple acyl-CoA dehydrogenase deficiency (MADD)(-like) patients with organ based
indication and efficacy of D,L-3-hydroxybutyrate treatment, with the numbers presented in the columns. Clinical improvement regarding liver symptoms included
hyperammonemia, hypoglycemia, and/or metabolic acidosis; clinical improvement regarding muscle symptoms included exercise intolerance, hypotonia, myo-
pathy, and/or rhabdomyolysis. b Kaplan–Meier curve of the survival in type II (n= 9) and type III (n= 14) MADD(-like) patients treated with D,L-3-HB compared
with the survival in historical controls from literature (type I [n= 16], type II [n= 26] and type III [n= 156] MADD) who were not reported to have been treated
with D,L-3-HB. c Kaplan–Meier plot that demonstrates the cumulative proportion of MADD(-like) patients with reported clinical improvement upon initiation of
D,L-3-HB treatment over time. Calculated from a total of 21 patients with sufficient data. HC historical control. x= censored patient.
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toward neurological symptoms. In addition to optimal dosing,
the most advantageous ratio between D-3-hydroxybutyrate
and L-3-hydroxybutyrate may need to be determined based
on (organ-specific) treatment indications.
Several methodological limitations concerning this study
should be considered. As this study concerned a retrospective
study collecting data over a period of >20 years, it was not
possible to consistently capture all detailed data, for instance
regarding specific time points. Second, the lack of standardized
clinical and biochemical outcome parameters made a detailed
study of efficacy difficult. Third, the assignment of outcome to
D,L-3-HB treatment was complicated by concurrent other
treatment options, and by a fluctuating natural disease course.
Finally, despite their best efforts, the authors have been unable
to include all centers with experience in this field.
Since the first publication in 2003,6 the story of D,L-3-HB for
MADD has become an excellent example of the long and
complex journey toward possible orphan drug designation and
registration of an unlicensed compound for the treatment of an
ultrarare, life-threatening disease. The strength of the current
study is the international pooling of data on the efficacy and
safety profile of D,L-3-HB in MADD(-like) patients. FAIR (i.e.,
findable, accessible, interoperable, reusable),42 evidence-based,
and transparent approaches are essential to establish sustain-
able orphan drugs.43,44 Therefore, the authors included
information on preparation and pricing of D,L-3-HB. Our
findings may be useful in the pursuit of orphan drug
designation and registration. To this aim, organizations such
as Fair Medicine,45 which introduces a coalition model that
involves all stakeholders in the pharmaceutical development
process, can perhaps bring a fresh impetus.
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